Last week Venetia Qendri presented her most recent work at the 2017 edition of the EUROGIN congress, which took place in Amsterdam from October 8 to October 11. This work concerns the health impact and cost-effectiveness of sex-neutral vaccination against HPV in Europe.
Most countries in Europe have currently established vaccination of preadolescent girls against HPV, but vaccine uptake in the girls-only programmes varies substantially between countries. Two dose schedules implemented since 2014 in combination with established procurement procedures for the HPV vaccine have reduced the total cost of vaccination in many national immunization programmes. These elements combined deem sex-neutral vaccination against HPV an appealing intervention for the improvement of the programmes. Hence, we expand our previously published framework developed for the Netherlands to evaluate the health impact and cost-effectiveness of sex-neutral vaccination against HPV in other European tender-based settings.